Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D05ALP
|
|||
| Former ID |
DNCL001880
|
|||
| Drug Name |
REG1
|
|||
| Indication | Acute coronary syndrome [ICD-11: BA41; ICD-9: 411.1] | Phase 3 | [1] | |
| Company |
Regado Biosciences
|
|||
| Structure |
 |
Download2D MOL
|
||
| Formula |
C20H40N3O11P
|
|||
| Canonical SMILES |
COCCOC(=O)NCCCCC(C(=O)NCCCCCCOP(=O)(O)O)NC(=O)OCCOC
|
|||
| InChI |
1S/C20H40N3O11P/c1-30-13-15-32-19(25)22-11-7-5-9-17(23-20(26)33-16-14-31-2)18(24)21-10-6-3-4-8-12-34-35(27,28)29/h17H,3-16H2,1-2H3,(H,21,24)(H,22,25)(H,23,26)(H2,27,28,29)
|
|||
| InChIKey |
QGVYYLZOAMMKAH-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 959716-28-0
|
|||
| PubChem Compound ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01848106) A Study To Determine the Efficacy and Safety of REG1 Compared to Bivalirudin in Patients Undergoing PCI. U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.